Monoclonal antibody-based sequential therapy for deep remission in multiple myeloma – MASTER trial
This research study will determine the frequency of minimal residual disease (MRD) after prescribed course of standard drug treatment, combined with daratumumab in participants with newly diagnosed multiple myeloma. Minimal residual disease is multiple myeloma cells below the level of that which we can detect with available technology today.
Newly diagnosed multiple myeloma
- Men and women at least 18 years of age who have been diagnosed with multiple myeloma
- No prior treatment for your multiple myeloma
18 - 99
Healthy Volunteers Needed
Duration of Participation
You will receive the study drugs for 14 to 22 months, depending on your response and MRD. After you finish the study drugs, the investigator will continue to watch you for side effects and follow your condition until you start a new treatment regimen.
Clinical Trials Information Line
University of Alabama at Birmingham Comprehensive Cancer Center